European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026
Long-term outcomes of contemporary durable left ventricular assist device support in younger patients: a European registry for patients with mechanical circulatory support (EUROMACS) analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gallone Guglielmo, Veen Kevin M, Bernhardt Alexander M, Caliskan Kadir, Najjar Emil, Netuka Ivan, Scandroglio Anna Mara, Spitaleri Antonio, Sangiorgi Diego, Ivak Peter, Fiane Arnt, Khaliel Feras, Özbaran Mustafa, Pya Yuri, Zimpfer Daniel, Färber Gloria, Gummert Jan, Meyns Bart, Quattroni Paola, Schoenrath Felix, De Ferrari Gaetano Maria, Rinaldi Mauro, Potapov Evgenij, Loforte Antonio
Аннотация
OBJECTIVES: Superior survival outcomes have been reported for younger patients receiving durable left ventricular assist devices (LVADs) in INTERMACS. We explored whether these findings extend to contemporary European practice leveraging on EUROMACS (European Registry for Patients with Mechanical Circulatory Support).
METHODS: Adult patients undergoing implantation of current-generation magnetically levitated LVADs in EUROMACS were stratified according to age groups. The primary outcome was 5-year on-device survival, censoring at heart transplantation (HT) or LVAD explantation. Secondary outcomes included LVAD explant for myocardial recovery, and survival free from major adverse events (bleeding, stroke, device-related infection, or device malfunction). Death incidence accounting for HT and support cessation as competing risks was also calculated.
RESULTS: A total of 2,850 patients undergoing HeartMate 3 implantation were included (<50 years: 23.5%; 50-59 years: 29.7%; 60-69 years: 38.0%; ≥70 years: 8.8%). Younger patients had fewer comorbidities, a higher prevalence of non-ischemic cardiomyopathy, and INTERMACS profile ≤3.Younger patients had superior on-device 5-yr survival (<50 years: 74.7%; 50-59 years: 65.5%; 60-69 years: 53.9%; ≥70 years: 48.8%; p < 0.001) and LVAD explantation for myocardial recovery (<50 years: 4.3%; 50-59 years: 1.8%; 60-69 years: 2.3%; ≥70 years: 0.4%; p = 0.031). Accounting for competing outcomes, the 5-year cumulative incidence of death was lowest among younger patients (<50 years: 20.8%; 50-59 years: 29.1%; 60-69 years: 40.8%; ≥70 years: 49.5%; p < 0.001), driven by higher HT rates. Survival free from bleeding was significantly higher in younger patients (p < 0.001). In contrast, 5-year freedom from stroke, device-related infection, and device malfunction was similar across age groups.
CONCLUSIONS: In contemporary European practice, patients <50 yrs undergoing LVAD implant had high 5-yr survival approaching that reported in cohorts of patients listed for HT. These findings support further investigation of prolonged LVAD support before HT as a potential strategy to maximize lifetime benefit in selected motivated younger candidates.
METHODS: Adult patients undergoing implantation of current-generation magnetically levitated LVADs in EUROMACS were stratified according to age groups. The primary outcome was 5-year on-device survival, censoring at heart transplantation (HT) or LVAD explantation. Secondary outcomes included LVAD explant for myocardial recovery, and survival free from major adverse events (bleeding, stroke, device-related infection, or device malfunction). Death incidence accounting for HT and support cessation as competing risks was also calculated.
RESULTS: A total of 2,850 patients undergoing HeartMate 3 implantation were included (<50 years: 23.5%; 50-59 years: 29.7%; 60-69 years: 38.0%; ≥70 years: 8.8%). Younger patients had fewer comorbidities, a higher prevalence of non-ischemic cardiomyopathy, and INTERMACS profile ≤3.Younger patients had superior on-device 5-yr survival (<50 years: 74.7%; 50-59 years: 65.5%; 60-69 years: 53.9%; ≥70 years: 48.8%; p < 0.001) and LVAD explantation for myocardial recovery (<50 years: 4.3%; 50-59 years: 1.8%; 60-69 years: 2.3%; ≥70 years: 0.4%; p = 0.031). Accounting for competing outcomes, the 5-year cumulative incidence of death was lowest among younger patients (<50 years: 20.8%; 50-59 years: 29.1%; 60-69 years: 40.8%; ≥70 years: 49.5%; p < 0.001), driven by higher HT rates. Survival free from bleeding was significantly higher in younger patients (p < 0.001). In contrast, 5-year freedom from stroke, device-related infection, and device malfunction was similar across age groups.
CONCLUSIONS: In contemporary European practice, patients <50 yrs undergoing LVAD implant had high 5-yr survival approaching that reported in cohorts of patients listed for HT. These findings support further investigation of prolonged LVAD support before HT as a potential strategy to maximize lifetime benefit in selected motivated younger candidates.